Amgen's best chance at breaking into the high-stakes obesity drug market got its start in a basement at the University of Iceland Science Park in Reykjavík, in a freezer chilled to minus-13 degrees Fahrenheit. Bloomberg's Madison Muller explains. (Source: Bloomberg)
Amgen's best chance at breaking into the high-stakes obesity drug market got its start in a basement at the University of Iceland Science Park in Reykjavík, in a freezer chilled to minus-13 degrees Fahrenheit. Bloomberg's Madison Muller explains. (Source: Bloomberg)
<iframe src="https://statesidedaily.com/embed/cluster/69563fa78c51149edb42adf071fb0e0bdbef9bc9" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="The Icelandic DNA Behind Amgen’s Hunt for the Next Ozempic"></iframe>